4 Largecap Promoter Backed High Margin Stocks to Watch for Future Multibagger Potential: Sun Pharma, HAL, Divi’s Labs and Torrent Pharma

Promoter backed high margin stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Sun Pharma, HAL, Divi’s Labs and Torrent Pharma meet that test, with market caps from Rs 1.75 lakh crore to Rs 4.27 lakh crore and Sun Pharma offering the fastest profit growth, 35.75% a year since FY22. Each of these companies has a promoter holding of at least 50 per cent and an operating margin of at least 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a promoter holding of at least 50 per cent and an operating margin of at least 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening promoter backed high margin stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 30 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Promoter Backed High Margin Stocks and Why Do They Attract Multibagger Interest?

Promoter backed high margin stocks are shares of large companies in which the promoters own at least half of the business and which keep at least twenty paise of operating profit from every rupee of sales. The four here cover pharmaceuticals, aerospace, pharmaceutical ingredients and drug making.

Owners with a large stake have their own wealth tied to the company, and a high operating margin shows that the business has pricing power and cost control worth backing. For promoter backed high margin stocks, both FY26 and the latest quarter showed growth. Whichever way you read promoter backed high margin stocks, the common thread is rising profit backed by complete financial data. A sensible way to study promoter backed high margin stocks is to look at profit growth, returns and valuation side by side. Below, each of promoter backed high margin stocks gets its own breakdown of growth, returns and valuation. Treat promoter backed high margin stocks as a research list, since share prices and rankings change with every earnings season.

Promoter Backed High Margin Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 30 October 2026. Sun Pharma has the lowest PE of the group at 35.25, while Torrent Pharma posts the highest return on equity at 25.49%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Sun Pharmaceutical Industries	1,777.70	4,27,161	35.25	36.42	13.74%	0.06	1,583.70 to 2,046.90
Hindustan Aeronautics	4,853.70	3,31,595	35.57	48.59	22.21%	0.00	3,479.10 to 5,149.90
Divi’s Laboratories	9,780	2,56,169	87.58	36.42	15.32%	0.00	5,647.50 to 9,780.00
Torrent Pharmaceuticals	4,613.40	1,75,124	81.23	36.42	25.49%	1.79	3,480.60 to 5,250.00

Sun Pharma: 35.75% Profit CAGR Since FY22

Sun Pharmaceutical Industries is one of India’s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 35.25 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.

HAL: Return on Equity of 22.21%

Hindustan Aeronautics is India’s state-owned aerospace company that designs, makes and services fighter jets, helicopters, engines and avionics. It reported FY26 revenue of Rs 36,787.95 crore, up 9.68% year on year, and net profit of Rs 9,115.52 crore, up 8.98%. Net profit has compounded at 15.74% a year since FY22, while revenue has grown 9.48% a year. Operating margin was 40.89% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

The stock trades at a PE of 35.57 against an industry PE of 48.59, below the sector average, with a return on equity of 22.21%. In the June 2026 quarter, revenue rose 15.26% to Rs 6,415.41 crore and net profit grew 14.88% to Rs 1,589.66 crore. The share price has gained 607.71% over five years. Domestic institutions raised their holding from 8.71% in September 2025 to 12.56% in September 2026.

Divi’s Labs: Debt-to-Equity of 0.00

Divi’s Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 71.04% over five years and 38.43% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026. The stock trades at a PE of 87.58 against an industry PE of 36.42, with a return on equity of 15.32%.

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

The stock trades at a PE of 81.23 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.

Promoter Backed High Margin Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these promoter backed high margin stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
Sun Pharma	61,673.94	11,564.52	12.69%	11.62%	11.93%	32.52%
HAL	36,787.95	9,115.52	9.68%	9.48%	15.26%	44.22%
Divi’s Labs	11,067	2,568	13.95%	5.09%	24.32%	42.82%
Torrent Pharma	13,886.15	2,138.18	20.34%	12.38%	56.29%	33.73%

Check the Univest Screener for live data on these promoter backed high margin stocks

Institutional Holding in Sun Pharma, HAL, Divi’s Labs and Torrent Pharma

Institutional holding shows who is backing these promoter backed high margin stocks alongside the promoter. The table uses the latest reported quarter for each. Divi’s Labs has the deepest institutional backing, with FII and DII together holding 39.55% as of September 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%), HAL (from 8.71% to 12.56%) and Torrent Pharma (from 9.28% to 12.87%).

Stock	Promoter	FII	DII	Public	Quarter
Sun Pharma	52.68%	14.36%	22.27%	10.70%	September 2026
HAL	71.64%	9.42%	12.56%	6.38%	September 2026
Divi’s Labs	51.88%	20.38%	19.17%	8.58%	September 2026
Torrent Pharma	60.78%	17.97%	12.87%	8.38%	July 2026

Risks to Weigh in Promoter Backed High Margin Stocks

Being careful with promoter backed high margin stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Divi’s Labs trades at a PE of 87.58 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Promoter Backed High Margin Stocks

Picking from promoter backed high margin stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.42 to 48.59) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Sun Pharma, HAL, Divi’s Labs and Torrent Pharma live prices.

Conclusion

Among promoter backed high margin stocks, Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, HAL for the biggest five-year price gain at 607.71%, Divi’s Labs for the strongest latest-quarter profit growth at 65.50% and Torrent Pharma for the highest return on equity at 25.49%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing promoter backed high margin stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Promoter Backed High Margin Stocks to Watch

Which are the best promoter backed high margin stocks to watch for multibagger potential?

Ans. Sun Pharma, HAL, Divi’s Labs and Torrent Pharma are the 4 names this list highlights, with market caps of Rs 4,27,161 crore, Rs 3,31,595 crore, Rs 2,56,169 crore and Rs 1,75,124 crore respectively. Sun Pharma is notable for the fastest profit growth, 35.75% a year since FY22. HAL stands out for the biggest five-year price gain at 607.71%. Divi’s Labs offers the strongest latest-quarter profit growth at 65.50%. Torrent Pharma brings the highest return on equity at 25.49%. These are watchlist names for promoter backed high margin stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Torrent Pharma a good stock for long-term investors?

Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.23 against an industry PE of 36.42 and a market cap of Rs 1,75,124 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in promoter backed high margin stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Sun Pharma become a multibagger from here?

Ans. Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in promoter backed high margin stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 35.25 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of Sun Pharma, HAL, Divi’s Labs and Torrent Pharma?

Ans. As of 30 October 2026, Sun Pharma has a market cap of Rs 4,27,161 crore, HAL has a market cap of Rs 3,31,595 crore, Divi’s Labs has a market cap of Rs 2,56,169 crore and Torrent Pharma has a market cap of Rs 1,75,124 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on promoter backed high margin stocks.

What are the risks of investing in promoter backed high margin stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Divi’s Labs trades at a PE of 87.58 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Divi’s Labs trading at a PE of 87.58?

Ans. Divi’s Labs’ PE of 87.58 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 15.32% and latest-quarter profit growth of 65.50%, which also means the stock is more sensitive if growth slows. Investors in promoter backed high margin stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Sun Pharma, HAL, Divi’s Labs and Torrent Pharma?

Ans. As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 21.98% of HAL (9.42% and 12.56%), 39.55% of Divi’s Labs (20.38% and 19.17%) and 30.84% of Torrent Pharma (17.97% and 12.87%). Rising institutional holding is a useful signal in promoter backed high margin stocks, though it should be read with earnings trends rather than on its own.